SAFE vs Convertible Notes: The Documentation Trap Founders Walk Into

## Introduction: The Documentation Problem Nobody Warns About

When we work with early-stage founders on seed financing, the conversation usually starts with valuation caps, interest rates, and conversion mechanics. Those details matter. But we've seen founders lose significant equity—sometimes 5-15% more than expected—because they overlooked provisions buried in the term sheet that most investors don't explicitly discuss.

The difference between a SAFE note and a convertible note isn't just structural. It's fundamentally about *who controls the conversion process and what documentation proves it happened*. We're going to walk through the specific clauses that create founder risk, how they differ between instruments, and what you need to negotiate before you sign.

## The Core Documentation Difference: Conversion Triggering

### How SAFE Notes Document Conversion

A SAFE note (Simple Agreement for Future Equity) is intentionally simple—typically 3-4 pages. That simplicity is a feature, but it creates a documentation gap founders don't anticipate.

When a SAFE note converts, there's no formal "conversion event" the way you might think. The conversion happens in one of these ways:

- **Priced Round**: When you raise a Series A or Series B, the SAFE automatically converts into whatever class of stock you're issuing (usually Series A preferred).
- **Liquidity Event**: If your company is acquired or goes public, the SAFE converts based on the agreement terms.
- **Dissolution Event**: If the company winds down, the SAFE holder gets cash according to the priority structure.

Here's what most founders miss: the SAFE doesn't specify *who decides* these conversion prices or mechanics. It references whatever documentation the priced round creates. That means **you're deferring critical terms to a future financing round**—a round where the SAFE investor may have different interests than you do.

In our work with early-stage founders, we've seen SAFE holders push for unfavorable Series A terms specifically because they know the SAFE will convert automatically. You don't have a negotiation point; you have an obligation.

### How Convertible Notes Document Conversion

Convertible notes are debt instruments with explicit conversion terms built into the note itself. The documentation is typically 10-15 pages and spells out:

- **Conversion price calculation**: The exact formula (discount rate, valuation cap, or weighted average)
- **Conversion timeline**: When conversion is mandatory vs. optional
- **Conversion event definitions**: What specifically triggers conversion (priced round threshold, time-based, acquisition price, etc.)
- **Maturity mechanics**: What happens if no conversion event occurs by the maturity date

Because convertible notes are debt, the documentation includes default provisions, interest accrual schedules, and investor rights if you miss payment obligations. This sounds worse, but it's actually more *explicit*. There's less ambiguity about what happens and when.

**The risk shift**: With a convertible note, you know exactly what triggers conversion. With a SAFE, you're betting that future documentation (your Series A term sheet) will be founder-friendly. Often, it's not.

## The Documentation Traps: What Founders Actually Overlook

### Trap 1: Pro-Rata Rights and Follow-On Language

Both SAFEs and convertible notes can include pro-rata rights (the investor's right to participate in future rounds to maintain their ownership percentage). But the documentation differs critically.

**In convertible notes**, pro-rata rights are explicitly negotiated as part of the note. The language defines:
- What counts as a "qualified financing" triggering pro-rata rights
- How the investor exercises the right (timing, mechanics)
- Whether the right survives if the investor doesn't participate

**In SAFE notes**, pro-rata rights aren't part of the SAFE itself. They're typically added as a side letter. This creates a documentation gap: What if the SAFE investor forgets to negotiate a side letter? What if the side letter references the SAFE but uses slightly different definitions of "follow-on round"?

We've seen founders run Series B with a SAFE investor claiming pro-rata rights based on a side letter that was loosely worded. The investor interpreted the definition of "financing" more broadly than the founders had assumed. That interpretation cost the founders an extra 2-3% dilution.

### Trap 2: Conversion Discount Rate Stacking

Here's a specific scenario we've navigated with clients:

You raise a $500K SAFE with a 20% discount rate and a $5M valuation cap.
Six months later, you raise another $500K SAFE from a different investor—same 20% discount rate, same $5M cap.
Two years later, you do your Series A at a $20M valuation.

Both SAFEs convert at a 20% discount, which means they convert at $16M valuation (80% of $20M). That's reasonable. But here's the hidden trap in SAFE documentation:

**Most SAFEs don't explicitly address what happens when multiple SAFEs exist.** The SAFE documentation says "conversion happens at the priced round valuation with this discount applied." It doesn't say *which SAFE* gets priority if there's a timing issue, or whether discount rates stack in ways that change the effective price.

Convertible notes explicitly address this in their documentation. The note specifies whether it's a "most favored nations" clause (if later notes have better terms, this note gets those terms too) or a "first-in, first-out" conversion sequence. The documentation is unambiguous.

With SAFEs, you're often left to assume conversion happens simultaneously. But if your Series A has a deadline and one SAFE investor can't sign the conversion agreement, you've got a documentation problem.

### Trap 3: Valuation Cap Ambiguity in Down Rounds

Convertible notes have explicit documentation about what happens if your company is acquired for less than the conversion price (a down round scenario).

A typical convertible note says: *"If the company is acquired at a price below the conversion price, the investor receives the greater of (a) conversion at the acquisition price, or (b) repayment of principal plus accrued interest."*

That's clear. The investor has a safety net.

SAFE notes don't have debt mechanics, so the documentation is vaguer: *"In a Liquidity Event, SAFE conversion is based on the valuation cap or discount, whichever is more favorable to the investor."*

But here's what founders miss: SAFE documentation doesn't typically include a repayment obligation if the valuation cap is breached. That means:

- If you're acquired at $10M and your SAFE has a $5M cap, the SAFE investor converts at $5M (getting a better deal).
- But if you're acquired at $2M and your SAFE cap is $5M, the investor converts at $2M (the actual price).
- The SAFE documentation typically doesn't guarantee the investor gets the full principal back.

We worked with a founder whose Series A fell apart, and they took an acquisition at $8M. Two SAFE investors with a $6M cap each demanded to convert at the cap, which would have reduced founder equity by 8%. The SAFE documentation didn't explicitly forbid this, even though the acquisition price was below the cap. It became a negotiation nightmare.

### Trap 4: Interest Accrual and Debt Treatment

Convertible notes accrue interest. The documentation specifies the rate (typically 5-8% annually) and how it compounds. When the note converts, the accrued interest converts into additional equity (increasing your dilution) or is paid in cash (if there's a repayment scenario).

The documentation is explicit: *"Interest accrues daily at X% annually and converts with the principal."*

SAFE notes are designed not to accrue interest—they're not debt instruments. But here's the subtle trap: Some SAFE term sheets include provisions that *act like* interest accrual without being labeled as such. For example:

- *"Upon a Liquidity Event, the SAFE investor's conversion amount is the greater of the invested amount or the invested amount adjusted for any subsequent down round."*

That's essentially interest by another name. It's a guaranteed return even if the company underperforms. But SAFE documentation often frames it as "downside protection" rather than "interest," which changes how it's treated for tax and accounting purposes.

Convertible notes are explicit: it's debt, it accrues interest, the documentation proves it. That clarity is important for your cap table and future financing.

## The Documentation Risk in Practice

Let's walk through a real scenario we've seen multiple times:

**The Setup:**
- Founder raises two SAFEs totaling $1M with a $10M cap, 20% discount
- No side letters documenting pro-rata rights (SAFE investors assumed they'd have them)
- 18 months later, Series A at $40M valuation

**The Problem:**
- First SAFE converted to Series A preferred at $8M valuation (20% discount off $10M cap... wait, cap is $10M, so actually converts at $10M valuation)
- But the Series A term sheet defines Series A conversion as including anti-dilution protection (weighted-average)
- SAFE documentation doesn't explicitly address how anti-dilution works for pre-round investors
- The two SAFE investors claim anti-dilution applies to them; the Series A investors say it doesn't (they're SAFEs, not preferred stock)
- Founder is now in a documentation fight that delays the Series A close by 6 weeks

Convertible note documentation would have specified this upfront. The note would say: *"This note is not subject to anti-dilution protection from subsequent financings."* Problem solved.

## Negotiating Documentation: What to Push On

### For SAFE Notes:

1. **Get pro-rata rights in writing as a side letter**, not as an assumption. Define:
- What counts as a "qualified round" (minimum check size, lead investor, etc.)
- Your allocation percentage if you choose to participate
- Timing for you to exercise the right

2. **Specify conversion priority** if you're raising multiple SAFEs:
- Do all SAFEs convert simultaneously, or in order?
- What if one investor can't execute conversion documentation by the closing deadline?

3. **Document anti-dilution position explicitly**:
- Your SAFE should say: *"SAFE investor waives anti-dilution rights in subsequent preferred stock financings."*
- If they won't waive it, you've got a bigger conversation about investor expectations.

### For Convertible Notes:

1. **Verify the most-favored-nations clause** is written the way you understand it:
- Does it apply only to discount rate, or to valuation cap too?
- If you later raise a note with better terms, does this note get upgraded?
- If so, does that trigger immediately, or only at conversion?

2. **Lock down the conversion event definition** with specificity:
- A "Series A" should mean a minimum financing (e.g., $2M+) with a designated lead investor
- A "priced round" should be distinguished from a bridge round or secondary offering
- Specify what percentage of new equity needs to be issued for it to count

3. **Clarify interest treatment at conversion**:
- Does accrued interest convert to equity, or is it paid in cash?
- If it converts, what class of stock does it convert into?
- Is the interest treated as part of the investor's equity stake for cap table purposes?

## Implications for Your Cap Table and Future Fundraising

These documentation differences have downstream effects [Series A Preparation: The Cap Table & Legal Readiness Test](/blog/series-a-preparation-the-cap-table-legal-readiness-test/).

When you go into Series A, your investors will receive a cap table showing all SAFEs and convertible notes and how they convert under their proposed valuation. If your SAFE and convertible note documentation contradict each other or lack clarity, your Series A investors will demand resolution *and additional legal fees to clean it up*. That costs you 5-10K in unexpected legal bills, plus it slows down your raise.

More importantly, the ambiguity signals to Series A investors that you didn't think through early financing mechanics. That's a yellow flag for operational rigor.

## The Operational Edge: Documentation and Accounting

From an accounting standpoint, SAFE notes and convertible notes are treated differently:

- **Convertible notes** are recorded as liabilities (debt) until conversion. They require interest expense tracking and contingent liability disclosure.
- **SAFE notes** are increasingly treated as equity (or quasi-equity) depending on your accounting firm's interpretation. This affects your financial statements.

The documentation determines how your auditor or accountant treats these instruments. If your SAFE documentation is vague about conversion triggers, your accountant will make conservative assumptions (often adding extra liability reserves). That inflates your reported debt and makes your balance sheet look worse to future investors.

Convertible notes have standardized accounting treatment because the documentation is explicit. You know how they'll show up in your financials.

## Practical Checklist: Before You Sign

- [ ] **SAFE or convertible note?** Understand which instrument and why (most startups lean SAFE for simplicity, but complexity may warrant convertible notes)
- [ ] **Conversion triggers**: Write them down. Be able to explain in one sentence when/how this converts.
- [ ] **Multiple instruments**: If you're raising more than one SAFE or note, document the conversion order and priority.
- [ ] **Pro-rata rights**: If promised, get them in a side letter with explicit definitions.
- [ ] **Valuation cap and discount**: Know the exact numbers and understand the conversion math (build a spreadsheet).
- [ ] **Interest or accrual**: Confirm whether interest applies and how it's treated at conversion.
- [ ] **Anti-dilution**: Confirm whether this investor waives anti-dilution in future preferred rounds.
- [ ] **Documentation quality**: Have a lawyer review before you sign. The $1-2K legal fee saves 10x in future complications.

## Conclusion: Documentation is Your Founder Protection

The SAFE vs. convertible note decision is often framed as "which is simpler?" But from our experience, the real question is *"which has documentation that protects my interests and scales to future fundraising?"*

SAFE notes are simpler on the surface, but they defer critical terms to future rounds. That simplicity becomes complexity later. Convertible notes are longer, but they're explicit, which gives you certainty.

Regardless of which you choose, the key principle is the same: **don't leave conversion mechanics, pro-rata rights, or valuation terms to assumption**. Get them documented, reviewed by legal counsel, and clearly understood by all parties.

When we work with founders on early-stage fundraising, this is one of the first things we tackle—not because it's flashy, but because it prevents costly mistakes later. Documentation that's clear today saves dilution and complexity tomorrow.

If you're about to raise seed capital and want to audit your term sheet before you sign, [contact Inflection CFO](/contact/) for a free financial audit. We'll review your SAFE or convertible note terms and flag the documentation risks you should negotiate.